πŸ“£ VC round data is live. Check it out!

CurveBeam AI Valuation Multiples

Discover revenue and EBITDA valuation multiples for CurveBeam AI and similar public comparables like EBM Technologies, Diagnos, MRSO, SenzaGen and more.

CurveBeam AI Overview

About CurveBeam AI

CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company’s CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.


Founded

2009

HQ

Australia

Employees

50

Financials (LTM)

Revenue: $8M
EBITDA: ($7M)

EV

$30M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

CurveBeam AI Financials

CurveBeam AI reported last 12-month revenue of $8M and negative EBITDA of ($7M).

In the same LTM period, CurveBeam AI generated $4M in gross profit, ($7M) in EBITDA losses, and had net loss of ($11M).

Revenue (LTM)


CurveBeam AI P&L

In the most recent fiscal year, CurveBeam AI reported revenue of $9M and EBITDA of ($7M).

CurveBeam AI is unprofitable as of last fiscal year, with gross margin of 45%, EBITDA margin of (83%), and net margin of (126%).

See analyst estimates for CurveBeam AI
LTMLast FY202320242025202620272028
Revenue$8M$9M$5M$7M$9M
Gross Profit$4M$4M$3M$3M$4M
Gross Margin45%45%51%45%45%
EBITDA($7M)($7M)($22M)($11M)($9M)
EBITDA Margin(92%)(83%)(426%)(171%)(109%)
EBIT Margin(133%)(121%)(293%)(232%)(159%)
Net Profit($11M)($11M)($27M)($14M)($12M)
Net Margin(139%)(126%)(510%)(214%)(139%)
Net Debtβ€”$8Mβ€”β€”β€”

Financial data powered by Morningstar, Inc.

CurveBeam AI Stock Performance

CurveBeam AI has current market cap of $21M, and enterprise value of $30M.

Market Cap Evolution


CurveBeam AI's stock price is $0.04.

CurveBeam AI share price decreased by 2.3% in the last 30 days, and by 37.0% in the last year.

CurveBeam AI has an EPS (earnings per share) of $-0.02.

See more trading valuation data for CurveBeam AI
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$30M$21M-0.1%-2.3%-12.7%-37.0%$-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

CurveBeam AI Valuation Multiples

CurveBeam AI trades at 3.8x EV/Revenue multiple, and (4.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for CurveBeam AI

EV / Revenue (LTM)


CurveBeam AI Financial Valuation Multiples

As of May 4, 2026, CurveBeam AI has market cap of $21M and EV of $30M.

CurveBeam AI has a P/E ratio of (1.9x).

LTMLast FY202320242025202620272028
EV/Revenue3.8x3.5x5.7x4.5x3.5x
EV/EBITDA(4.2x)(4.2x)(1.3x)(2.6x)(3.2x)
EV/EBIT(2.9x)(2.9x)(2.0x)(1.9x)(2.2x)
EV/Gross Profit8.5x7.7x11.3x9.9x7.7x
P/E(1.9x)(1.9x)(0.8x)(1.4x)(1.7x)
EV/FCF(4.1x)(4.1x)(1.9x)(2.5x)(3.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified CurveBeam AI Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

CurveBeam AI Margins & Growth Rates

In the most recent fiscal year, CurveBeam AI reported gross margin of 45%, EBITDA margin of (83%), and net margin of (126%).

See estimated margins and future growth rates for CurveBeam AI

CurveBeam AI Margins

Last FY20242025202720282029
Gross Margin45%45%45%
EBITDA Margin(83%)(171%)(109%)
EBIT Margin(121%)(232%)(159%)
Net Margin(126%)(214%)(139%)
FCF Margin(84%)(182%)(96%)

CurveBeam AI Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth28%30%
Gross Profit Growth14%29%
EBITDA Growth(49%)(17%)
EBIT Growth1%(11%)
Net Profit Growth(46%)(16%)
FCF Growth(24%)(31%)

Data powered by FactSet, Inc. and Morningstar, Inc.

CurveBeam AI Operational KPIs

CurveBeam AI's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.

Access forward-looking KPIs for CurveBeam AI
Last FY202320242025202620272028
Revenue per Employee$0.2Mβ€”β€”β€”
Opex per Employee$0.4Mβ€”β€”β€”
S&M Expenses to Revenue7%17%11%7%
G&A Expenses to Revenue131%195%176%131%
R&D Expenses to Revenue4%9%7%4%
Opex to Revenue204%344%277%204%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

CurveBeam AI Competitors

CurveBeam AI competitors include EBM Technologies, Diagnos, MRSO, SenzaGen, NanoRepro, Cambridge Cognition, Biosynex, CareView Communications, NextPlat and Welby.

Most CurveBeam AI public comparables operate across Medical Imaging & Diagnostics, Healthcare Software, HealthTech, B2B SaaS and Vertical SaaS.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
EBM Technologies2.3xβ€”20.3xβ€”
Diagnos249.7xβ€”(7.3x)β€”
MRSO1.3x1.3x(47.2x)β€”
SenzaGen2.9xβ€”(20.2x)β€”
NanoRepro2.5x0.7x(3.5x)(9.4x)
Cambridge Cognition1.7x1.6x(32.9x)299.4x
Biosynex0.7xβ€”(3537.5x)β€”
CareView Communications4.9xβ€”246.0xβ€”

This data is available for Pro users. Sign up to see all CurveBeam AI competitors and their valuation data.

Start Free Trial

CurveBeam AI Funding History

Before going public, CurveBeam AI raised $25M in total equity funding, across 1 round.


CurveBeam AI Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Feb-23Undisclosed stageAcorn Capital Inv Fd; Firetrail Investments; Frazis Capital Partners; Ilwella; Karst Peak Capital; SG Hiscock and Company; Tenmile$25Mβ€”CurveBeam AI is a developer and manufacturer of specialized medical imaging equipment, specifically cone beam CT scanners designed for weight-bearing diagnostic imaging in orthopedics and bone health assessment. The company combines point-of-care diagnostic imaging hardware with artificial intelligence and deep learning software solutions to automate clinical assessment, including proprietary tools to calculate structural fragility scores for fracture risk evaluation. CurveBeam was formed in October 2022 through a merger of CurveBeam LLC and StraxCorp Pty Ltd, with global operations headquarters in Hatfield, Pennsylvania for product development and manufacturing, and a corporate office in Melbourne, Australia for AI research and regulatory functions. The company completed a pre-IPO private placement on 2 February 2023, raising A$25 million from investors including Tenmile (Andrew Forrest's investment firm), Firetrail Investments, Ilwella, and Karst Peak Capital, among others. The round was oversubscribed, originally targeted at A$15 million, with CEO Greg Brown investing an additional A$1 million personally. CurveBeam forecasted A$11 million in revenue for the 12 months to 30 June 2023, driven primarily by sales of its flagship HiRise weight-bearing CT scanner. The company successfully listed on the Australian Securities Exchange in late August 2023 via a A$25 million IPO at A$0.48 per share, giving it an indicative market capitalization of A$153.7 million upon listing under ticker code CVB. Proceeds from the IPO were allocated to expanded sales and marketing, continued research and development into CT and AI imaging technologies, and clinical trials for new products including the InReach compact imaging device targeted for commercialization in 2026.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About CurveBeam AI

When was CurveBeam AI founded?CurveBeam AI was founded in 2009.
Where is CurveBeam AI headquartered?CurveBeam AI is headquartered in Australia.
How many employees does CurveBeam AI have?As of today, CurveBeam AI has over 50 employees.
Is CurveBeam AI publicly listed?Yes, CurveBeam AI is a public company listed on Australian Securities Exchange.
What is the stock symbol of CurveBeam AI?CurveBeam AI trades under CVB ticker.
When did CurveBeam AI go public?CurveBeam AI went public in 2023.
Who are competitors of CurveBeam AI?CurveBeam AI main competitors include EBM Technologies, Diagnos, MRSO, SenzaGen, NanoRepro, Cambridge Cognition, Biosynex, CareView Communications, NextPlat, Welby.
What is the current market cap of CurveBeam AI?CurveBeam AI's current market cap is $21M.
What is the current revenue of CurveBeam AI?CurveBeam AI's last 12 months revenue is $8M.
What is the current EV/Revenue multiple of CurveBeam AI?Current revenue multiple of CurveBeam AI is 3.8x.
Is CurveBeam AI profitable?No, CurveBeam AI is not profitable.
What is the current EBITDA of CurveBeam AI?CurveBeam AI has negative EBITDA and is not profitable.
What is CurveBeam AI's EBITDA margin?CurveBeam AI's last 12 months EBITDA margin is (92%).
What is the current EV/EBITDA multiple of CurveBeam AI?Current EBITDA multiple of CurveBeam AI is (4.2x).
What is the current FCF of CurveBeam AI?CurveBeam AI's last 12 months FCF is ($7M).
What is CurveBeam AI's FCF margin?CurveBeam AI's last 12 months FCF margin is (93%).
What is the current EV/FCF multiple of CurveBeam AI?Current FCF multiple of CurveBeam AI is (4.1x).
How many companies CurveBeam AI has acquired to date?CurveBeam AI hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies CurveBeam AI has invested to date?CurveBeam AI hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to CurveBeam AI

Lists including CurveBeam AI

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial